Nyrada Announces Positive Results for Xolatryp in Liver Cancer Study
Key points
- Xolatryp shows significant anti-tumour activity in liver cancer model
- Combination with doxorubicin shows enhanced efficacy
- Patent application filed for Xolatryp as anti-cancer agent
Full summary
Nyrada Inc. announced that its lead drug candidate, Xolatryp, demonstrated clear anti-tumour activity in a preclinical model of liver cancer. The study showed that Xolatryp, both as a monotherapy and in combination with doxorubicin, significantly reduced tumour volume. The combination treatment exhibited the greatest reduction in tumour volume and was well tolerated. A provisional patent application for Xolatryp as an anti-cancer agent has been lodged.
Outlook
Nyrada plans to further evaluate Xolatryp across additional tumour types and in combination with other anti-cancer agents.
Summary generated by a large language model. Please interpret with care.